Accuray Incorporated (ARAY)
| Market Cap | 51.22M |
| Revenue (ttm) | 436.97M |
| Net Income (ttm) | -35.62M |
| Shares Out | 118.78M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 390,228 |
| Open | 0.455 |
| Previous Close | 0.445 |
| Day's Range | 0.431 - 0.455 |
| 52-Week Range | 0.330 - 2.100 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 3.50 (+711.69%) |
| Earnings Date | May 6, 2026 |
About ARAY
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidne... [Read more]
Financial Performance
In fiscal year 2025, Accuray's revenue was $458.51 million, an increase of 2.68% compared to the previous year's $446.55 million. Losses were -$1.59 million, -89.77% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ARAY stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 711.69% from the latest price.
News
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference cal...
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as...
Accuray Earnings Call Transcript: Q2 2026
Q2 FY2026 revenue fell 12% year-over-year to $102.2M, driven by lower China product sales amid tariffs and geopolitical headwinds, while service revenue grew 4%. FY2026 guidance was cut to $440–$450M revenue and $22–$25M adjusted EBITDA, reflecting ongoing external pressures.
Accuray Reports Fiscal 2026 Second Quarter Financial Results
MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference ...
Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push
Accuray Incorporated (NASDAQ: ARAY) announced the first phase of a broad strategic, operational and organizational transformation designed to tighten cost controls, clarify accountability and accelera...
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy. Workforce optimization ac...
Accuray Earnings Call Transcript: Q1 2026
Q1 revenue declined 7% year-over-year, with product sales down in EMEA and China, but service revenue grew 7%. Guidance for fiscal 2026 is unchanged, with revenue expected to rebound in the second half as order timing improves. Transformation efforts target margin expansion and sustainable growth.
Accuray Reports Fiscal 2026 First Quarter Financial Results
MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis. , Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve, the company's new Ch...
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
MADISON, Wis. , Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference...
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor Chan W.
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Radiation Treatments for More Communities Across Australia. MADISON, Wis.
Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
MADISON, Wis. , Sept. 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced today the signing of a memor...
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
New Solution Provides an Unprecedented Set of Tools, Empowering Clinical Teams With Choice and Flexibility to Deliver Adaptive Care—Tailoring Radiotherapy to Each Patient's Unique Needs MADISON, Wis. ...
Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025
Event Will Feature Global KOLs Sharing Their Perspectives on the Role of Adaptive Radiotherapy in Radiation Medicine MADISON, Wis. , Sept. 11, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) ...
Accuray Earnings Call Transcript: Q4 2025
Q4 revenue declined 5% year-over-year to $128M, but full-year revenue hit a record $459M, up 3%. Service revenue and margins grew, and a major debt refinancing improved financial flexibility. FY2026 guidance is $471M–$485M in revenue and $31M–$35M in adjusted EBITDA.
Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results
Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the...
Accuray to Report Fourth Quarter Fiscal 2025 Financial Results on August 13, 2025
MADISON, Wis. , July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended June 30, 2025, during a conference cal...
Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities
MADISON, Wis. , June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous pote...
Accuray Transcript: Jefferies Global Healthcare Conference 2025
The company is expanding its addressable market with new products targeting emerging regions, while actively mitigating tariff impacts through supply chain strategies and duty programs. Service revenue and margin expansion remain central, with a shift toward subscription models and global pricing improvements.
Accuray to Participate in the Jefferies Global Healthcare Conference 2025
MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated ...
Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System
Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis. , May 5, 2025 /PRNewswire/ -- Accura...
Accuray Earnings Call Transcript: Q3 2025
Q3 revenue grew 12% year-over-year, driven by strong product and service demand, with Adjusted EBITDA up to $6M. Tariff-related headwinds are expected to impact Q4 China sales by $10M-$15M, but guidance is maintained as mitigation efforts and global demand offset risks.